Is HUM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Demographic tailwind in Medicare Advantage, with revenue (ttm) at ~$146 billion. The bear case rests on the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Analysts covering it are spread from $280.00 to $596.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $280.00, -32.2% from the $413.16 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Demographic tailwind in Medicare Advantage. The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. The most optimistic analyst target on HUM is $596.00, +44.3% from the $413.16 price. That figure is only reachable if this thesis works close to its best case.

The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Margins remain thin, with a trailing operating margin near 3.5% and net margin under 1%. Earnings are also seasonal: consensus calls for an adjusted loss of about $1.00 per share in Q3 2026 and about $7.86 in Q4, as Medicare Advantage costs build through the year. Star ratings are a second lever; the 2027 rebound helps, but ratings are recalculated every year and a slip would reduce CMS quality-bonus payments. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing, such as the 2027 PPO exits, can pressure profitability or cause member attrition if benefits are trimmed too far, and after a roughly 58% rally in 2026 more of the recovery is already priced in. The most pessimistic published target is $280.00, -32.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Demographic tailwind in Medicare Advantage) stalling in the reported numbers rather than in the narrative, the risk above (the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals and risk tolerance, and this is not advice. The bull case is the aging-population tailwind, Humana's Medicare Advantage scale, CenterWell, a star-ratings rebound to about 95% of members in four-star-or-better plans, and a margin recovery toward roughly 3% by 2028. The bear case is that medical costs and reimbursement changes could keep margins thin, and the stock is already up about 58% in 2026. Weigh both and your own situation.

Humana is a health insurer focused on government programs, especially Medicare Advantage, where it covered about 7.1 million members in early 2026. It also serves Medicaid and military TRICARE members. Through its CenterWell arm it operates pharmacy, senior primary care, and home-health businesses, aiming to coordinate care and capture more of the healthcare dollar for its own members.

Yes. Humana pays a quarterly dividend of about $0.885 per share, about $3.54 a year, which works out to roughly a 0.8% yield at a share price near $417 in October 2026. The yield has fallen as the stock rallied. The company has paid and generally raised its dividend for many consecutive years and also repurchases stock, though dividend policy can change with earnings and is set by the board.